TUCSON, Ariz., April 18, 2016 — The Critical Path Institute (C-Path), the Special Programme for Research and Training in Tropical Diseases (TDR), TB Alliance, andSt. George’s, University of London, are pleased to announce the launch of the TB-Platform for Aggregation of Clinical TB Studies (TB-PACTS). “TB-PACTS is a valuable tool in the fight against the […]
TUCSON, Ariz., April 29, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB) clinical trial data sharing platform. The initiative will start by creating a common database from three Phase III clinical trials earlier supported by the Special Programme for Research and Training in Tropical Diseases (TDR), the […]
CPTR highlights its fifth anniversary with the launch of a new website, which reflects the coalition’s evolved focus on the next set of opportunities and challenges facing the development and introduction of novel TB regimens.
Recognizing an international need for a centralized, standardized data resource for globally diverse genomic and other clinically relevant tuberculosis data, the Critical Path to TB Drug Regimens (CPTR) initiative has begun development and implementation of a Rapid Drug Susceptibility Test (RDST) data-sharing platform in partnership with the Critical Path Institute (C-Path), FIND, the New Diagnostics […]
STAND trial will test the first regimen designed to significantly shorten and simplify the treatment of drug-sensitive and drug-resistant TB SEATTLE (April 23, 2014)—Based on positive results from earlier clinical studies, TB Alliance is advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global […]
Expansion will help synergize R&D of TB regimens and drug susceptibility tests to maximize impact of new TB tools.
The Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens initiative launches guidelines that will facilitate the involvement of communities and participants in the conduct of TB drug trials.
The Critical Path to TB Drug Regimens (CPTR) is pleased to announce the launch of its inaugural Advisory Board.
The Critical Path to TB Drug Regimens (CPTR) today announced an innovative agreement between AstraZeneca, Bayer, Sanofi, Tibotec, TB Alliance, and the World Health Organization to share information on tuberculosis (TB) compounds within their respective drug pipelines.
Critical Path Institute (C-Path) announced that the Regulatory Science Consortium, an arm of CPTR, has added 10 new member organizations, including some of the world’s leading pharmaceuitcal developers